Table 2.
Transplant characteristics
| Characteristics | n | % |
|---|---|---|
| Donor source | ||
| Sibling | 41 | 37 |
| Matched unrelated donor | 61 | 55 |
| Mismatched | 8 | 7 |
| Female donor to male recipient | ||
| No | 90 | 82 |
| Yes | 20 | 18 |
| Stem cell source | ||
| Peripheral blood | 109 | 99 |
| Bone marrow | 1 | 1 |
| PB CD34+, ×106/kg | ||
| Median | 6.4 | |
| Range | 2-14 | |
| CMV serostatus patient/donor | ||
| Negative/negative | 36 | 33 |
| Positive/positive | 33 | 30 |
| Other | 41 | 37 |
| Time diagnosis to allo-HSCT, d | ||
| Median | 110 | |
| Range | 56-05 | |
| Time start CT2 to allo-HSCT, d | ||
| Median | 62 | |
| Range | 37-21 | |
| Time evaluation CT2 to allo-HSCT, d | ||
| Median | 16 | |
| Range | 1-66 | |
| Median follow-up for surviving patients, mo | 23 | |
| EBMT risk score | ||
| 0 | 2 | 2 |
| 1 | 4 | 3 |
| 2 | 35 | 32 |
| 3 | 59 | 54 |
| 4 | 8 | 7 |
Data are number of patients, percentage of the entire patient sample (N = 110), unless stated otherwise.
CMV, cytomegalovirus; CT, chemotherapy; EBMT, European Group of Blood and Marrow Transplantation; PB, peripheral blood.